COVID-19 Update - This is to inform you that the Government of India has announced a complete lockdown in India 22nd March 2020 to 3rd May 2020. As a result, our offices will now be closed till 3rd May 2020 and all our employees will be working from home. Office telephones will not be answered, and therefore you are requested to direct all your queries related to manuscript submission, review process, publication etc. at below mentioned details.,, Mob. 8826373757, 8826859373, 9910947804

Print ISSN:-2581-5725

Online ISSN:-2456-9267


Current Issue

Year 2020

Volume: 5 , Issue: 1

Article Access statistics

Viewed: 481

Emailed: 0

PDF Downloaded: 196

IP Archives of Cytology and Histopathology Research

Evaluation of osteonectin as a diagnostic marker of osteogenic bone tumors

Full Text PDF Share on Facebook Share on Twitter

Author Details : Murad Ahmad, Sadaf Mirza, Kafil Akhtar, Rana K. Sherwani, Khalid A Sherwani

Volume : 3, Issue : 2, Year : 2018

Article Page : 93-100

Suggest article by email


Introduction: Immunohistochemistry plays an important but limited role in the diagnosis of primary bone tumors. Sometimes it is very difficult to differentiate osteosarcomas histologically from other tumors with similar morphology but with different malignant potential and treatment protocol. The correct diagnosis of OSA relies on identification of osteoid production by malignant cells which can be detected by the use of osteonectin.
Materials and Methods: The present study was carried out on 200 patients of benign and malignant lesions of bone. After a detailed clinical history and local examination, paraffin section of resected specimens were studied by hematoxylin and eosin and immunohistochemical stain, osteonectin and matrix was graded on a four-tiered grading system with statistical analysis of osteonectin positivity in osteogenic bone tumours and tumour-like lesions.
Results: Benign and malignant tumours accounted for 74.6% and 25.0% of the total cases. Osteoid production were seen in 36 cases (100.0%) of osteosarcomas, followed by fibrous dysplasia in 18 cases (100.0%) and osteoid osteoma in 10 cases (100.0%). Both polygonal and spindle shaped tumour cells in osteosarcoma showed Grade 4 positivity with osteonectin. Fibroblastic variant of osteosarcoma showed diffuse (Grade 4) and focal strong staining (Grade 2) alternating with negative areas. Chondroblastic variant of osteosarcoma showed Grade 4+ immunoreactivity in conventional osteosarcoma like areas, whereas chondrocyte- like tumour cells surrounded by chondro-osteoid –like matrix showed well- defined osteonectin staining.
Conclusions: Osteonectin is a helpful osteogenic marker for establishing the diagnosis of osteoblastic origin of a tumour that produce no or scarcely any matrix.

Keywords: Bone Tumors, Immunohistochemistry, Osteonectin.

Doi : 10.18231/2456-9267.2018.0019

How to cite : Ahmad M, Mirza S, Akhtar K, Sherwani R K, Sherwani K A, Evaluation of osteonectin as a diagnostic marker of osteogenic bone tumors. IP Arch Cytol Histopathol Res 2018;3(2):93-100

Copyright © 2018 by author(s) and IP Arch Cytol Histopathol Res. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (CC-BY-NC 4.0) (